Tempest Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Tempest Therapeutics, Inc. (TPST) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$11.65 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-13.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2019-11-13
- Tempest Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2019-09-30 was -$11.65M.
- Tempest Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2019-06-30 was -$9.87M.
- Tempest Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2019-03-31 was -$10.38M.
- Tempest Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2018-12-31 was -$10.46M.
- Tempest Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2018 was -$27.05M.
- Tempest Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2017 was -$84.57M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$11.65M 10-Q · filed 2019-11-13 | -$21.52M derived: sum of 2 quarters · filed 2019-11-13 | -$31.89M 10-Q · filed 2019-11-13 | -$42.35M derived: sum of 4 quarters · filed 2019-11-13 |
| 2019-06-30 | -$9.87M 10-Q · filed 2019-08-12 | -$20.25M 10-Q · filed 2019-08-12 | -$30.70M derived: sum of 3 quarters · filed 2019-08-12 | -$38.23M derived: sum of 4 quarters · filed 2019-11-13 |
| 2019-03-31 | -$10.38M 10-Q · filed 2019-05-15 | -$20.83M derived: sum of 2 quarters · filed 2019-05-15 | -$28.36M derived: sum of 3 quarters · filed 2019-11-13 | -$33.18M derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-12-31 | -$10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$17.98M derived: sum of 2 quarters · filed 2019-11-13 | -$22.81M derived: sum of 3 quarters · filed 2019-11-13 | -$27.05M 10-K · filed 2019-04-01 |
| 2018-09-30 | -$7.53M 10-Q · filed 2019-11-13 | -$12.35M derived: sum of 2 quarters · filed 2019-11-13 | -$16.59M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$4.82M 10-Q · filed 2019-08-12 | -$9.07M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$4.25M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$84.57M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |